Abstract：
Deposition of amyloid and tau pathology can be quantified in vivo using positron emission tomography (PET). Accurate longitudinal measurements of accumulation from these images are critical for characterizing the start and spread of the disease. However, these measurements are challenging; precision and accuracy can be affected substantially by various sources of errors and variability. This review, supported by a systematic search of the literature, summarizes the current design and methodologies of longitudinal PET studies. Intrinsic, biological causes of variability of the Alzheimer\'s disease (AD) protein load over time are then detailed. Technical factors contributing to longitudinal PET measurement uncertainty are highlighted, followed by suggestions for mitigating these factors, including possible techniques that leverage shared information between serial scans. Controlling for intrinsic variability and reducing measurement uncertainty in longitudinal PET pipelines will provide more accurate and precise markers of disease evolution, improve clinical trial design, and aid therapy response monitoring.
摘要：
淀粉样蛋白和tau病理的沉积可以使用正电子发射断层扫描(PET)在体内定量。来自这些图像的累积的准确纵向测量对于表征疾病的开始和传播至关重要。然而,这些测量是具有挑战性的;精度和准确性会受到各种误差和可变性来源的实质性影响。这次审查,在文献系统搜索的支持下，总结了当前纵向PET研究的设计和方法。内在,然后详细说明阿尔茨海默病（AD）蛋白质负荷随时间变化的生物学原因。强调了导致纵向PET测量不确定度的技术因素，其次是减轻这些因素的建议，包括利用串行扫描之间共享信息的可能技术。控制纵向PET管道的内在变异性和降低测量不确定性将提供更准确和精确的疾病演变标记。改进临床试验设计，和辅助治疗反应监测。
